Bone marrow transplantation in a child with hemophagocytic lymphohistiocytosis using a less toxic conditioning regimen.
BACKGROUND
Hemophagocytic lymphohistiocytosis (HLH) is a rare non-neoplastic, frequently fatal disease of childhood. HLA-matched bone marrow transplantation (BMT) can bring about long-term remission and an eventual cure.


METHODS
We report on the beneficial effect of BMT in a 2-month-old male using a less intensive conditioning regimen. The regimen included busulfan at 4 mg/kg/day (total dose 16 mg/kg), etoposide at 300 mg/m2/day (total dose 900 mg/m2), and cyclophosphamide at 50 mg/kg/day (total dose 150 mg/kg). Prophylaxis for graft-vs.-host disease included methotrexate and cyclosporine.


RESULTS
An absolute neutrophil count of 500 microL was noticed on + day 12 (engraftment day). At present, i.e., 400 days after the procedure, the patient is asymptomatic, his physical examination is normal, and a slightly increased level of gamma-glutamyl-transpeptidase (GGT) and alkaline phosphatase are the only laboratory abnormalities.


CONCLUSIONS
In this case, the conditioning regimen was adequate for the eradication of the disease and allowed persistent engraftment without significant toxicity. The results in our patient suggest that a less toxic regimen is feasible and permits rapid engraftment without compromising the effectiveness of chemotherapy.
González-Llano
O
O
Servicio de Hematología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Mancías-Guerra
C
C
Cantú-Rodríguez
O G
OG
Hernández-Garza
N E
NE
Quiroga-Rivera
A
A
Herrera-Garza
J L
JL
Jaime-Pérez
J C
JC
Gómez-Almaguer
D
D
D016026:Bone Marrow Transplantation; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male